Biogen Inc

NASDAQ:BIIBUnited States

Biogen Inc. is a global biopharmaceutical company focused on discovering, developing, and delivering advanced therapies for people living with serious and complex diseases worldwide. It has a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA), Alzheimer's disease, and amyotrophic lateral sclerosis (ALS). It is focused on advancing its pipeline in neurology, specialized immunology, and rare diseases. The Company’s marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of Friedreich's Ataxia; QALSODY for the treatment of ALS; and FUMADERM for the treatment of severe plaque psoriasis. It also has collaborations for the commercialization of LEQEMBI, ZURZUVAE, RITUXAN, RITUXAN HYCELA, GAZYVA, OCREVUS, LUNSUMIO, and COLUMVI. It commercializes a portfolio of biosimilars of advanced biologics including BENEPALI, IMRALDI, FLIXABI, and BYOOVIZ.

Contact Information

Headquarters

225 Binney StreetCAMBRIDGE, MA, United States 02142

Phone

781-464-2000

Fax

302-636-5454

Executives

Independent Chairman of the Board

Caroline Dorsa

President, Chief Executive Officer, Director

Christopher Viehbacher

Chief Financial Officer, Executive Vice President

Michael McDonnell

Chief Human Resource Officer, Executive Vice President

Ginger Gregory

Executive Vice President, Chief Legal Officer, Secretary

Susan Alexander